Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies.
Antibodies
Neutralization
SARS-CoV-2
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
08 Mar 2021
08 Mar 2021
Historique:
pubmed:
25
3
2021
medline:
25
3
2021
entrez:
24
3
2021
Statut:
epublish
Résumé
Antibodies elicited in response to infection undergo somatic mutation in germinal centers that can result in higher affinity for the cognate antigen. To determine the effects of somatic mutation on the properties of SARS-CoV-2 spike receptor-binding domain (RBD)-specific antibodies, we analyzed six independent antibody lineages. As well as increased neutralization potency, antibody evolution changed pathways for acquisition of resistance and, in some cases, restricted the range of neutralization escape options. For some antibodies, maturation apparently imposed a requirement for multiple spike mutations to enable escape. For certain antibody lineages, maturation enabled neutralization of circulating SARS-CoV-2 variants of concern and heterologous sarbecoviruses. Antibody-antigen structures revealed that these properties resulted from substitutions that allowed additional variability at the interface with the RBD. These findings suggest that increasing antibody diversity through prolonged or repeated antigen exposure may improve protection against diversifying SARS-CoV-2 populations, and perhaps against other pandemic threat coronaviruses.
Identifiants
pubmed: 33758864
doi: 10.1101/2021.03.07.434227
pmc: PMC7987023
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : K99 AI153465
Pays : United States
Commentaires et corrections
Type : UpdateIn
Déclaration de conflit d'intérêts
Declaration of Interests The Rockefeller University has filed provisional patent applications in connection with this work on which M.C.N. (US patent 63/021,387) and Y.W., F.S., T.H. and P.D.B. (US patent 63/036,124) are listed as inventors.
Références
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Annu Rev Immunol. 2012;30:429-57
pubmed: 22224772
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Immunity. 2020 Jul 14;53(1):98-105.e5
pubmed: 32561270
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
Cell. 2020 Sep 17;182(6):1663-1673
pubmed: 32946786
Science. 2020 Aug 21;369(6506):1010-1014
pubmed: 32540901
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Science. 2020 Aug 28;369(6507):1119-1123
pubmed: 32661058
Elife. 2020 Oct 28;9:
pubmed: 33112236
Nat Methods. 2012 Sep;9(9):853-4
pubmed: 22842542
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Nucleic Acids Res. 2015 Jan;43(Database issue):D413-22
pubmed: 25378316
Nat Commun. 2021 Jun 21;12(1):3815
pubmed: 34155209
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
J Infect Dis. 2021 Feb 13;223(3):389-398
pubmed: 33140086
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
J Mol Biol. 1993 Dec 5;234(3):779-815
pubmed: 8254673
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
Science. 2021 Feb 12;371(6530):735-741
pubmed: 33436524
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
J Exp Med. 2019 Oct 7;216(10):2253-2264
pubmed: 31350309
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Emerg Infect Dis. 2021 Apr;27(4):
pubmed: 33567247
Nature. 2009 Apr 2;458(7238):636-40
pubmed: 19287373
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nat Commun. 2020 Oct 27;11(1):5413
pubmed: 33110068
Methods Enzymol. 2011;487:545-74
pubmed: 21187238
Cell. 2013 Mar 28;153(1):126-38
pubmed: 23540694
Nat Methods. 2018 Nov;15(11):905-908
pubmed: 30377346
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
Sci Immunol. 2021 Feb 23;6(56):
pubmed: 33622975
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4
pubmed: 33535027
Nature. 2020 Jul;583(7815):282-285
pubmed: 32218527
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
Cell Mol Immunol. 2020 Jun;17(6):647-649
pubmed: 32313207
Curr Biol. 2020 Apr 6;30(7):1346-1351.e2
pubmed: 32197085
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Science. 2020 Jun 12;368(6496):1274-1278
pubmed: 32404477
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
J Clin Microbiol. 2020 Nov 18;58(12):
pubmed: 32917729
Science. 2020 Nov 20;370(6519):950-957
pubmed: 32972994
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
J Mol Biol. 1993 Dec 20;234(4):946-50
pubmed: 8263940
Cell. 2020 Nov 25;183(5):1298-1311.e11
pubmed: 33125897
J Struct Biol. 2005 Oct;152(1):36-51
pubmed: 16182563
Cell. 2021 Mar 4;184(5):1201-1213.e14
pubmed: 33571429
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Protein Sci. 2018 Jan;27(1):14-25
pubmed: 28710774
Science. 2005 Oct 28;310(5748):676-9
pubmed: 16195424
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
Curr Opin Virol. 2019 Feb;34:149-159
pubmed: 30884330